MUC1 and idiopathic pulmonary fibrosis: The role of KL-6 as a therapeutic biomarker during IPF acute exacerbations has been tested in AE-IPF patients treated with a high dose of corticosteroids; the survived patients presented a reduction in KL-6 levels [77].